Pharmacokinetic interaction between glucocorticoids and tacrolimus after renal transplantation

doi:10.5246/jcps.2019.04.026

Abstract

Abstract:

There is an interaction between tacrolimus (TAC) and glucocorticoids where glucocorticoids is a known CYP3A4 and P-gp inducer. However, the dose of glucocorticoids reported is low but not pulse therapy. We retrospectively studied 63 renal transplant recipients receiving TAC after transplantation. All the patients were classified as 500 mg (POD 1–3), 30 mg (POD 4–10), 25 mg (POD 11–17), 20 mg (POD 18–24), 15 mg (POD 25–31), 10 mg (POD 32–60) and 10 mg (POD 61–90). We recorded daily data for each patient from the day of transplantation until POD 90. There was no difference in TAC blood levels within the 3 months after transplantation in the glucocorticoids groups. However, the average daily dose of TAC was significantly lower by weekly reductions of 5 mg dose. The TAC daily dose was not changed from POD 1–4, but the blood concentrations of TAC were significantly lower after the glucocorticoid dose was changed from 500 mg to 30 mg. We demonstrated the induction effect of low-dose glucocorticoids on TAC in renal transplant recipients, and found that the high-dose of glucocorticoids might play a role in substrate competition. We proposed that monitoring of the blood concentrations of TAC was needed when the glucocorticoid dose was changed in the patient undergoing renal transplantation.

Key words: Interaction, Tacrolimus, Glucocorticoids, Pharmacokinetic, CYP3A4

CLC Number:

R969.1

Supporting:

Hui Yang, Xiaopeng Hu, Xiongyong Yang, Hang Liu, Liang Ren, Wei Wang, Lihong Liu, Xiaodong Zhang. Pharmacokinetic interaction between glucocorticoids and tacrolimus after renal transplantation[J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(4): 257-263.

References

[1] Anglicheau, D.; Flamant, M.; Schlageter, M.H.; Martinez, F.; Cassinat, B.; Beaune, P.; Legendre, C.; Thervet, E. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol. Dial. Transplant. 2003, 18, 2409-2414.

[2] Filler, G.; Grygas, R.; Mai, I.; Stolpe, H.J.; Greiner, C.; Bauer, S.; Ehrich, J.H. Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol. Dial. Transplant. 1997, 12, 1668-1671.

[3] Lampen, A.; Christians, U.; Guengerich, F.P.; Watkins, P.B.; Kolars, J.C.; Bader, A.; Gonschior, A.K.; Dralle, H.; Hackbarth, I.; Sewing, K.F. Metabolism of the immuno-suppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab. Dispos. 1995, 23, 1315-1324.

[4] Tanaka, K.; Hirai, M.; Tanigawara, Y.; Yasuhara, M.; Hori, R.; Ueda, K.; Inui, K. Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein. Pharm. Res. 1996, 13, 1073-1077.

[5] Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN / SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplant, 2011, 24.

[6] Hesselink, D.A.; Ngyuen, H.; Wabbijn, M.; Gregoor, P.J.; Steyerberg, E.W.; van Riemsdijk, I.C.; Weimar, W.; van Gelder, T. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br. J. Clin. Pharmacol. 2003, 56, 327-330.

[7] Shihab, F.S.; Lee, S.T.; Smith, L.D.; Woodle, E.S.; Pirsch, J.D.; Gaber, A.O.; Henning, A.K.; Reisfield, R.; Fitzsimmons, W.; Holman, J. First for the Astellas Corticosteroid Withdrawal Group. Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study. Am. J. Transplant. 2013, 13, 474-484.

[8] van Duijnhoven, E.M.; Boots, J.M.; Christiaans, M.H.; Stolk, L.M.; Undre, N.A.; van Hooff, J.P. Increase in tacrolimus trough levels after steroid withdrawal. Transpl. Int. 2003, 16, 721-725.

[9] Smith, LD.; Allard, JA.; Corbett, J.; Nelson, E.; Shihab, F. Tacrolimus nephrotoxicity as a result of steroid withdrawal in renal transplant recipients. Am. J. Transplant. 2005, 5 (Suppl 11), 159.

[10] Christians, U.; Jacobsen, W.; Benet, L.Z.; Lampen, A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin. Pharmacokinet. 2002, 41, 813-851.

[11] Gibson, G.G.; Plant, N.J.; Swales, K.E.; Ayrton, A.; El-Sankary, W. Receptor-dependent transcriptional activation of cytochrome P4503A genes: Induction mechanisms, species differences and interindividual variation in man. Xenobiotica. 2002, 32, 165-206.

[12] Geick, A.; Eichelbaum, M.; Burk, O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 2001, 276, 14581-14587.

[13] Undre, N.A.; Schäfer, A. Factors affecting the pharma-cokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant. Proc. 1998, 30, 1261-1263.

[14] Sinclair, N.R. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ. 1992, 147, 645-657.

[15] Kasiske, B.L.; Chakkera, H.A.; Louis, T.A.; Ma, J.Z. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J. Am. Soc. Nephrol. 2000, 11, 1910-1917.

[16] Rostaing, L.; Cantarovich, D.; Mourad, G.; Budde, K.; Rigotti, P.; Mariat, C.; Margreiter, R.; Capdevilla, L.; Lang, P.; Vialtel, P.; Ortuño-Mirete, J.; Charpentier, B.; Legendre, C.; Sanchez-Plumed, J.; Oppenheimer, F.; Kessler, M. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation. 2005, 79, 807-814.

[17] Vítko, S.; Klinger, M.; Salmela, K.; Wlodarczyk, Z.; Tydèn, G.; Senatorski, G.; Ostrowski, M.; Fauchald, P.; Kokot, F.; Stefoni, S.; Perner, F.; Claesson, K.; Castagneto, M.; Heemann, U.; Carmellini, M.; Squifflet, J.P.; Weber, M.; Segoloni, G.; Bäckman, L.; Sperschneider, H.; Krämer, B.K. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: Results of the Atlas study. Transplantation. 2005, 80, 1734-1741.

[18] Serrano, O.K.; Kandaswamy, R.; Gillingham, K.; Chinnakotla, S.; Dunn, T.B.; Finger, E.; Payne, W.; Ibrahim, H.; Kukla, A.; Spong, R.; Issa, N.; Pruett, T.L.; Matas, A. Rapid discontinuation of prednisone in kidney transplant recipients: 15-year outcomes from the university of minnesota. Transplantation. 2017, 101, 2590-2598.

[19] Khwaja, K.; Asolati, M.; Harmon, J.; Melancon, J.K.; Dunn, T.; Gillingham, K.; Kandaswamy, R.; Humar, A.; Gruessner, R.; Payne, W.; Najarian, J.; Dunn, D.; Sutherland, D.; Matas, A.J. Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients. Am. J. Transplant. 2004, 4, 980-987.

[20] Matas, A.J.; Kandaswamy, R.; Gillingham, K.J.; McHugh, L.; Ibrahim, H.; Kasiske, B.; Humar, A. Prednisone-free maintenance immunosuppression-a 5-year experience. Am. J. Transplant. 2005, 5, 2473-2478.

[21] Rizzari, M.D.; Suszynski, T.M.; Gillingham, K.J.; Dunn, T.B.; Ibrahim, H.N.; Payne, W.D.; Chinnakotla, S.; Finger, E.B.; Sutherland, D.E.; Kandaswamy, R.; Najarian, J.S.; Pruett, T.L.; Kukla, A.; Spong, R.; Matas, A.J. Ten-year outcome after rapid discontinuation of prednisone in adult primary kidney transplantation. Clin. J. Am. Soc. Nephrol. 2012, 7, 494-503.